PressAugust 26, 2026 SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board
PressAugust 26, 2026 Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
PressAugust 24, 2026 SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
PressAugust 18, 2026 SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
PressAugust 14, 2026 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
PressAugust 14, 2026 Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
PressAugust 12, 2026 SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
PressAugust 12, 2026 Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
PressAugust 6, 2026 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
PressAugust 6, 2026 Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
PressAugust 6, 2026 Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026
PressAugust 6, 2026 GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
PressAugust 6, 2026 Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin
PressAugust 5, 2026 Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PressAugust 5, 2026 SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
PressAugust 5, 2026 Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
PressAugust 5, 2026 Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
PressJuly 31, 2026 SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
PressJuly 30, 2026 Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
